AUPH vs. PCVX, KRYS, CYTK, RYTM, PTCT, SRPT, RNA, SWTX, RARE, and AKRO
Should you be buying Aurinia Pharmaceuticals stock or one of its competitors? The main competitors of Aurinia Pharmaceuticals include Vaxcyte (PCVX), Krystal Biotech (KRYS), Cytokinetics (CYTK), Rhythm Pharmaceuticals (RYTM), PTC Therapeutics (PTCT), Sarepta Therapeutics (SRPT), Avidity Biosciences (RNA), SpringWorks Therapeutics (SWTX), Ultragenyx Pharmaceutical (RARE), and Akero Therapeutics (AKRO). These companies are all part of the "pharmaceutical products" industry.
Aurinia Pharmaceuticals vs.
Aurinia Pharmaceuticals (NASDAQ:AUPH) and Vaxcyte (NASDAQ:PCVX) are both medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their risk, media sentiment, valuation, institutional ownership, earnings, dividends, community ranking, analyst recommendations and profitability.
36.8% of Aurinia Pharmaceuticals shares are held by institutional investors. Comparatively, 96.8% of Vaxcyte shares are held by institutional investors. 4.3% of Aurinia Pharmaceuticals shares are held by company insiders. Comparatively, 3.1% of Vaxcyte shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.
Aurinia Pharmaceuticals currently has a consensus target price of $11.50, indicating a potential upside of 38.30%. Vaxcyte has a consensus target price of $136.50, indicating a potential upside of 305.35%. Given Vaxcyte's stronger consensus rating and higher probable upside, analysts clearly believe Vaxcyte is more favorable than Aurinia Pharmaceuticals.
Aurinia Pharmaceuticals has higher revenue and earnings than Vaxcyte. Vaxcyte is trading at a lower price-to-earnings ratio than Aurinia Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
Aurinia Pharmaceuticals received 522 more outperform votes than Vaxcyte when rated by MarketBeat users. However, 78.57% of users gave Vaxcyte an outperform vote while only 73.41% of users gave Aurinia Pharmaceuticals an outperform vote.
In the previous week, Vaxcyte had 2 more articles in the media than Aurinia Pharmaceuticals. MarketBeat recorded 16 mentions for Vaxcyte and 14 mentions for Aurinia Pharmaceuticals. Vaxcyte's average media sentiment score of 1.37 beat Aurinia Pharmaceuticals' score of 0.57 indicating that Vaxcyte is being referred to more favorably in the news media.
Vaxcyte has a net margin of 0.00% compared to Aurinia Pharmaceuticals' net margin of -10.23%. Aurinia Pharmaceuticals' return on equity of -4.41% beat Vaxcyte's return on equity.
Aurinia Pharmaceuticals has a beta of 1.16, meaning that its share price is 16% more volatile than the S&P 500. Comparatively, Vaxcyte has a beta of 1.27, meaning that its share price is 27% more volatile than the S&P 500.
Summary
Vaxcyte beats Aurinia Pharmaceuticals on 11 of the 18 factors compared between the two stocks.
Get Aurinia Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for AUPH and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Aurinia Pharmaceuticals Competitors List
Related Companies and Tools
This page (NASDAQ:AUPH) was last updated on 5/22/2025 by MarketBeat.com Staff
Buy AUPH Stock Free AUPH Stock Alerts